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A B S T R A C T
A comprehensive toxicokinetic analysis of citrinin (CIT) revealed interspecies differences for all toxicokinetic
parameters and in absolute oral bioavailability. Oral bioavailability for CIT was complete for broilers
(113–131%), while ranging from 37 to 44% in pigs. CIT was more rapidly absorbed in pigs (Tmax = 0.92 h)
compared to broiler chickens (Tmax = 7.33 h). The elimination of CIT was slower in pigs (T1/2el = 26.81 h after
intravenous (IV) administration) compared to chickens (T1/2el = 1.97 h after IV administration), due to the
striking difference in clearance (Cliv=9.87 mL/h/kg for pigs versus Cliv = 863.09 mL/h/kg for broilers). Also,
the volume of distribution differed significantly between pigs (Vd = 0.30 L/kg after IV administration) and
chickens (Vd = 2.46 L/kg after IV administration). However, plasma protein binding did not differ statistically
significant (91–98%). It is imperative to further investigate biotransformation and elimination pathways in
different species, including humans.
1. Introduction
Mycotoxins are secondary fungal metabolites which can cause toxic
effects such as hepatotoxicity, carcinogenicity, and nephrotoxicity in
both humans and animals (Bennett and Klich, 2003). For this reason,
many toxins have been extensively studied during the last decades.
However, data and knowledge about citrinin (CIT) are limited. CIT is a
mycotoxin mainly produced post-harvest in food and feed by Monascus,
Aspergillus and Penicillium fungal species (Korzybski et al., 1967; Friis
et al., 1969; Scott et al., 1972; Blanc et al., 1995; Council for
Agricurtural Science and Technology, 2003). The presence of CIT is
common in feed (incidence of CIT in chicken and pig feed was> 45%)
(Meerpoel et al., 2018) and food, as recent studies revealed high pre-
valence of CIT and its metabolite dihydrocitrinone (HO-CIT) in 90% of
human urine samples (Föllmann et al., 2014; Ali et al., 2015;
Huybrechts et al., 2014; Heyndrickx et al., 2015). A study from López
Sánchez et al. generated occurrence data for CIT in European foodstuffs
(López Sánchez et al., 2017). A total of 1,195 food samples were col-
lected from 8 EU countries. CIT was detected in 105 samples, of which
61 samples were quantified. The red yeast rice samples (n = 92) were
found to be most prone to CIT contamination. CIT was detected in 40%
of the samples and 3 samples exceeded the maximum limit of 2,000 μg/
kg. The data from this study imply that CIT exposure is common among
the population, but its potential risks for public health are still unclear.
Repeated dose animal experiments in dogs (Kitchen et al., 1977), rab-
bits (Kumar et al., 2014), chickens (Mehdi et al., 1981) and rats (Singh
et al., 2007) showed the kidney to be the major target of CIT toxicity.
Regarding this nephrotoxicity of CIT, a no observed adverse effect level
(NOAEL) of 20 μg/kg per kg body weight (BW) was determined for
humans by the European Food Safety Authority (EFSA) (European Food
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Safety Authority (EFSA), 2012). However, it is uncertain whether this
NOAEL applies for other toxic effects such as genotoxicity and carci-
nogenicity, resulting in CIT to be categorized in group 3 of the Inter-
national Agency for Research on Cancer (IARC) classification, i.e. not
classifiable as to its carcinogenicity to humans (International Agency
for Research on Cancer, 1986).
Both CIT and OTA are produced by Penicillium and Aspergillus spe-
cies (Wood et al., 2003). This explains why OTA and CIT often co-occur
in feed and foodstuffs (Meerpoel et al., 2018). Various studies report an
antagonistic, synergistic or additive effect between both toxins, as re-
viewed in (Speijers and Speijers, 2004).
Risk assessment could not be completed for CIT, due to the lack of
toxicity and toxicokinetic data. A first human toxicokinetic study with
two volunteers who ingested citrinin was performed including 24 h
urine and blood collection (Degen et al., 2018). However, there are no
other existing data for CIT to the best of our knowledge. Therefore,
EFSA published a scientific opinion on CIT whereby the need for ad-
ditional quantitative toxicity data in humans and experimental animals
was emphasized (European Food Safety Authority (EFSA), 2012). In
toxicology studies, the pig showed to be a relevant experimental animal
model for humans because of the similarities of the gastro-intestinal
tract, liver and kidney (Swindle et al., 2012; Gasthuys et al., 2016).
Moreover, the pig is also an important animal for livestock production.
Hence, CIT exposure may impair animal health and performance which
imply economic losses and reduced animal welfare. Also, it is important
to study other animals such as chickens because several differences
have been found among animal species in mycotoxin metabolism (Vidal
et al., 2018a). The different gastro-intestinal anatomy and physiology
compared to humans and pigs, further contribute to the relevance of
performing research on CIT in chickens. An adequate risk assessment
could not yet be performed for chickens, nor for pigs, due to the lack of
toxicokinetic and toxicity data.
Accordingly, the present study aims to gather toxicokinetic data,
including absolute oral bioavailability, concerning CIT by using the pig
as animal model for man. The pig has already been used successfully by
our research group as a model for toxicokinetic studies with other
mycotoxins for humans, including children (Devreese et al., 2015;
Schelstraete et al., 2019; Catteuw et al., 2019). The second aim was to
investigate the plasma protein binding of CIT, as it is a thriving factor in
major toxicokinetic processes such as body distribution. Furthermore,
to investigate interspecies differences in toxicokinetics and plasma
protein binding, a second toxicokinetic experiment using broiler
chickens was included. To our knowledge, no toxicokinetic nor plasma
protein binding studies for CIT in pigs or chickens have been reported
before. Furthermore, the results of this study were compared to the
toxicokinetic parameters of OTA.
2. Materials and methods
2.1. Chemicals and reagents
CIT (Fig. 1) was purchased from Fermentek (Jerusalem, Israel) and
HO-CIT (Fig. 1) was obtained from Analyticon (Potsdam, Germany).
Stock solutions of 1 mg/mL were prepared in methanol (MeOH). A
dissolved standard of 13C-labeled CIT (13C13-CIT) as internal standard
(IS) in acetonitrile (ACN) was purchased from Biopure-Romer Labs
(Tulln, Austria), with a concentration of 10.6 μg/mL. All stock solutions
were stored at −20 °C. From the individual stock solutions, a CIT/HO-
CIT standard mixture of 10 μg/mL each and a13C13-CIT solution of
100 ng/mL were prepared in MeOH. A Milli-Q SP Reagent water system
(Merck Millipore, Darmstadt, Germany) was used to obtain ultrapure
water. MeOH (LC-MS grade, 99.95%) was purchased from BioSolve BV
(Valkenswaard, The Netherlands), ACN (HiPerSolv Chromanorm HPLC
grade, 99.9%) was acquired from VWR International (Leuven, Bel-
gium), whereas ammonium acetate (98%) and glacial acetic acid (HAc,
100%) were purchased from Merck.
2.2. Animals and experimental procedures
Eight conventional pigs (hybrid sow x Piétrain boars, 4 males and 4
females, 10 weeks old, mean BW ± standard deviation (SD)
21 ± 1.7 kg) and 8 broiler chickens (Ross 308, 4 males and 4 females,
3 weeks old, BW 1.3 ± 0.3 kg) were housed according to Directive
(2010)/63/EU (European Commission, 2010) and the Belgian Royal
Decree on the protection of laboratory animals of 29 May 2013 (FPS
Public Health, 2013). For one week, the animals were acclimatized and
socialized in the stables. Water and control feed was given ad libitum.
After one week, a double-lumen catheter was surgically placed into
the external jugular veins of the pigs according to a previously de-
scribed procedure (Gasthuys et al., 2009). After surgery, the animals
were individually housed, and heating lamps were placed to prevent
hypothermia. Surgical wounds were treated frequently using chlorte-
tracycline (Chlortetra-spray®, Eurovet Animal Health, The Nether-
lands). Bandages were replaced when needed. Clinical parameters were
recorded daily, i.e. rectal body temperature, BW, feed and water up-
take, clinical appearance and wound healing.
Before the start of the toxicokinetic experiment, the animals were
deprived of feed for 12 h. Next, 4 pigs and 4 broilers were administered
CIT (50 μg/kg BW for pigs, 250 μg/kg BW for chickens) by oral gavage
(PO), whereas the other 4 animals were injected the equal dose of CIT
by intravenous (IV) injection in the jugular catheter (pigs) or the bra-
chial wing vein (chickens). The dose was based on preliminary pilot
studies. The PO and IV bolus solutions were prepared by dissolving the
CIT standard in ethanol (10 mg/mL) and further diluting with water
(PO) or physiological saline (IV) up to a volume of 1 mL. Following
administration of the mycotoxin, 0.5 mL of blood was drawn from the
jugular vein (pigs) or leg vein (chickens) in vacutainers containing
ethylenediaminetetraacetic (EDTA) at various time points: 0 (just be-
fore administration) and at 5, 10, 20, 30, 45, 60 min, 2, 4, 6, 8, 12, 24,
36, 48 and 72 h post administration. Samples were centrifuged
(8,517×g, 10 min, 4 °C) within 2 h after collection, and aliquots of
plasma (250 μL) were stored at ≤−18 °C until analysis. After a four-
day wash-out period, the protocol was repeated in a two-way crossover
design; i.e. animals that first received an IV injection of the mycotoxin
then received a PO bolus and vice versa. The dosing, blood collection,
and sample storage were performed in the same way as in the first
administration period. After the animal trial, the animals were eu-
thanized by injecting an overdose of sodium pentobarbital (Sodium
Fig. 1. Chemical structures of A) citrinin (CIT), B) dihydrocitrinone (HO-CIT) and C) ochratoxin A (OTA). Note the structural similarities between the molecules.
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pentobarbital 20%®, Kela, Hoogstraten, Belgium) in the jugular veins or
wing veins. The animal experiment was approved by the Ethical
Committee of the Faculty of Veterinary Medicine and the Faculty of
Bioscience Engineering of Ghent University (EC, 2017/105).
2.3. Sample preparation
2.3.1. Plasma extraction for LC-MS/MS analysis
2.3.1.1. Pig plasma. To 225 μL of blank plasma, 25 μL of a CIT/HO-CIT
working solution (1, 5, 10, 50, 100, 500, 1000, 2000 ng/mL) was added
to construct a matrix-matched calibration curve with concentrations of
0.1, 0.5, 1, 5, 10, 50, 100 and 200 ng/mL. For blank samples as well as
the study samples, aliquots of 250 μL were used. The blank plasma was
obtained from pigs that did not receive a CIT dose during the trial. Two
quality control samples were included at a concentration of 10 and
100 ng/mL. All samples were spiked with 10 μL of the 100 ng/mL IS
solution. Next, 750 μL of ACN were added and samples were vortexed
for 15 s, followed by centrifugation for 10 min at 4,517×g at 4 °C.
Supernatants were transferred to plastic tubes and evaporated to
dryness under a gentle stream of nitrogen at 40 ± 5 °C. The residue
was reconstituted in 250 μL of injection solvent (H2O:MeOH, 50:50,
v:v) and the sample was transferred to a chromatography vial for
injection.
2.3.1.2. Chicken plasma. Aliquots of 90 μL plasma were pipetted in
wells of an Oasis Ostro® protein precipitation and phospholipid removal
96-well plate (Waters, Zellik, Belgium). Ten μL of each CIT/HO-CIT
working solution (1, 5, 10, 50, 100, 500, 1000, 2000 ng/mL) was added
to construct a matrix-matched calibration curve with concentrations of
0.1, 0.5, 1, 5, 10, 50, 100 and 200 ng/mL. For blank and study samples,
aliquots of 100 μL were used. Two quality control samples were
included in a concentration of 10 and 100 ng/mL. All samples were
spiked with 10 μL of the 100 ng/mL IS solution. Next, a mixture of
ACN:formic acid (99.9:0.1, v:v) was added, reaching a total volume of
400 μL and samples were manually mixed for 15 s by moving the
sample in and out a pipette tip. Then, vacuum was applied on the
Ostro® plate (75 mm Hg) during 15 min. Filtrates were collected in a
96-well plate and transferred to plastic tubes followed by evaporation
to dryness under a gentle stream of nitrogen at 40 °C. The residue was
reconstituted in 100 μL of injection solvent (H2O:MeOH, 50:50, v:v)
and the sample was transferred to a chromatography vial.
2.3.2. Plasma protein binding
Plasma protein binding of CIT was evaluated by spiking fresh blank
chicken and pig plasma at 5, 25 and 50 ng of CIT/mL. Samples were
kept at pig and chicken body temperature (39 °C and 41 °C respectively)
in order to achieve the same physiological circumstances for protein
binding as in vivo. At each concentration level, samples were divided in
3 aliquots of 500 μL (aliquot 1, aliquot 2 and aliquot 3). Aliquot 1
followed the sample pretreatment as described above. Aliquot 2 and 3
were incubated in a heated water bath at 39 °C for 1 h. Next, aliquots 2
and 3 were transferred onto Amicon® Ultra centrifugal devices and
centrifuged (8,517×g, 15 min, 39 °C). From the filtered aliquots,
100 μL was transferred to Eppendorf® cups and 20 μL of IS solution
(100 ng/mL) and 150 μL of water were added and mixed. The samples
were treated further on in a similar way as aliquot 1. Corresponding
matrix-matched calibration curves were used for CIT quantification.
Plasma protein binding was assessed at each concentration level (5, 25
and 50 ng/mL) using equation (1).
=
−C C
C
xPlasma protein binding (%)   100Aliquot average Aliquot and
Aliquot
1 2 3
1
(1)
2.3.3. LC-MS/MS analysis and method validation
Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
analysis was performed with an Acquity UPLC system coupled to a
Waters Xevo® TQ-S triple quadrupole mass spectrometer (Waters
Table 1
Mass spectrometric parameters of citrinin (CIT), dihydrocitrinone (HO-CIT) and13C13-labeled citrinin (13C13-CIT).
Analyte Retention time (min) Precursor ion Cone voltage (V) Product ion m/z (Collision energy)
m/z Ions Quantifier Qualifier
CIT 3.70 281.00 [M + MeOH–H]- 50.0 249.00 (15.0 V) 205.00 (25.0 V)
13C13-CIT 3.70 294.00 [M + MeOH–H]- 50.0 262.00 (15.0 V) –
HO-CIT 2.80 265.00 [M + MeOH–H]- 60.0 221.00 (16.0 V) 177.00 (20.0 V)
Table 2a
Validation parameters for citrinin (CIT) and dihydrocitrinone (HO-CIT) in pig plasma for linearity (r and gof, 6 calibration points ranging from LOQ-200 ng/mL), limit
of detection (LOD), limit of quantification (LOQ), matrix effects (SSE), extraction recovery (RE) and apparent recovery (RA), the latter calculated using area (without
internal standard (IS) or using response (with IS)).
Compound Correlation coefficient (r) Goodness-of-fit (gof) (%) LOD (ng/mL) LOQ (ng/mL) SSE (%) RA (%) RE (%)
Without IS With IS
CIT 0.9984 5.1 0.05 0.1 35.9 45.2 110.2 79.5
HO-CIT 0.9967 7.5 0.01 0.1 32.1 29.5 96.9 91.7
Table 2b
Validation parameters for citrinin (CIT) and dihydrocitrinone (HO-CIT) in chicken plasma for linearity (r and gof, 6 calibration points ranging from LOQ-200 ng/mL),
limit of detection (LOD), limit of quantification (LOQ), matrix effects (SSE), extraction recovery (RE) and apparent recovery (RA), the latter calculated using area
(without internal standard (IS) or using response (with IS)).
Compound Correlation coefficient (r) Goodness-of-fit (gof) (%) LOD (ng/mL) LOQ (ng/mL) SSE (%) RA (%) RE (%)
Without IS With IS
CIT 0.9979 15.8 0.05 0.1 77.3 71.0 107.5 91.9
HO-CIT 0.9954 10.1 0.01 0.1 69.2 76.0 96.5 79.7
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Table 3a
Validation results for accuracy, within-day (n = 6) and between-day (n = 3x3) precision at low (LOQ), medium (10 ng/mL) and high (200 ng/mL) concentration
level for pigs.
Compound Accuracy (%) Precision (RSD, %)
LOQ 10 ng/mL 200 ng/mL LOQ 10 ng/mL 200 ng/mL
Within-day CIT −9.8 8.4 −1 28.6 4.4 3.7
HO-CIT −11.8 1.4 0.4 25.4 4.6 2.4
Between-day CIT −3.7 9.4 −1.8 21.3 5.4 6.7
HO-CIT 15.9 2.8 −0.8 42.1 4.5 6.9
Table 3b
Validation results for accuracy, within-day (n = 6) and between-day (n = 3x3) precision at low (LOQ), medium (10 ng/mL) and high (200 ng/mL) concentration
level for broiler chickens.
Compound Accuracy (%) Precision (RSD, %)
LOQ 10 ng/mL 200 ng/mL LOQ 10 ng/mL 200 ng/mL
Within-day CIT −7.7 −25.2 −8.2 4.9 4.2 3.0
HO-CIT 12.6 −9.6 −10.2 2.6 9.3 10.1
Between-day CIT 4.1 −12.6 3.9 10.7 14.3 9.9
HO-CIT −25.6 −12.9 −5.1 4.6 10.1 7.2
Fig. 2. Plasma concentration-time profile of citrinin (CIT) after a single intravenous (IV, triangles) and oral bolus (PO, dots) of (A) 0.05 mg/kg body weight to 8 pigs
(4 ♂/4 ♀) and (B) 0.25 mg/kg body weight to 8 chickens (4 ♂/4 ♀). Results are presented as mean values ± standard deviation (SD). The insert shows IV
administration in pigs in more detail.
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Technologies, Zellik, Belgium) equipped with an electrospray interface.
Masslynx® and Targetlynx® software 4.1 (Waters Corp., Milford, MA,
USA) were used for data acquisition and processing. Chromatographic
separation was achieved using an Acquity UPLC HSS T3
(1.8 μm × 2.1 × 100 mm) column (Waters). Column and autosampler
temperature were set at 40 °C and 10 °C, respectively. Gradient elution
was established with a mobile phase consisting of 0.05% HAc (v/v) and
5 mM ammonium acetate in water (eluent A) and MeOH (eluent B) at a
flow rate of 0.4 mL/min. A run started with a linear increase of B from
30% to 90% during 6.5 min, followed by an instant increase to 100% B
maintaining these conditions up to 9 min, after which column re-
equilibration took place for 1 min, resulting in a total run time of
10 min. Mass spectrometry (MS) analyses were carried out using mul-
tiple reaction monitoring (MRM) with negative electrospray ionization
(ESI−) (Table 1).
The method was validated for CIT and HO-CIT to meet the criteria
of European Commission (EC) decision No. 2002/65732 and
Commission Regulation (EU) No. 401/2006 (European Commission,
2006) as guidance. Specificity was determined by evaluating the pre-
sence of interfering chromatographic peaks in 15 representative blank
samples. Linearity of three matrix-matched calibration curves
(0.1–200.0 ng/mL) as well as calibration curves in neat solvent
(0.1–200.0 ng/mL) was evaluated on three different days using the
coefficient of determination (R2) and confirmed by calculation of the
goodness-of-fit coefficient (gof, %). Limit of detection (LOD) and limit of
quantification (LOQ) (ng/mL) were determined based on the signal-to-
noise (S/N) ratio according to the guidelines of the International Con-
ference of Harmonisatio, (ICH) (International Conference on
Harmonisation, 2005). Therefore, blank plasma samples were spiked in
decreasing concentrations within the range based on expected LOD and
LOQ levels determined during method optimization (0.05–10.0 ng/
mL). The samples were analyzed as described above and the experiment
was conducted in three independent replicates. Accuracy (%) is defined
as the ratio between the measured concentration and the actual
(spiked) concentration. Therefore, blank samples were spiked at three
different concentration levels: LOQ level, 10 and 200 ng/mL. The ob-
served concentration was calculated in triplicate from a matrix-mat-
ched calibration curve and compared with the spiked concentration.
Intraday precision (repeatability) and interday precision (intermediate
precision) were determined by calculating the residual standard de-
viation (RSD, %), respectively RSDr and RSDR. According to Commis-
sion Decision (2002)/657/EC, precision values should not exceed the
level calculated by the Horwitz equation (Equations (2) and (3)) were C
represents the mass fraction expressed as a power of 10.
RSDr = 2/3 (2[1−0.5logC]) (2)
RSDR = 2[1−0.5logC] (3)
For concentrations lower than 100 ng/mL, the Horwitz equation can
result in too high values (> 20%). For these concentrations, precision
values should be as low as possible (European Commission, 2002).
Matrix effects were assessed following the approach described by Sulyok
et al. (2006). Calibration curves for CIT and HO-CIT in neat solvent
were constructed by plotting signal intensity against concentration. In
the same way, calibration curves of CIT in extracts were made up by
plotting signal intensity of the analyte in spiked samples before and
after extraction versus spiked concentration. Signal suppression/en-
hancement (SSE, equation (4)), apparent recovery (RA, equation (5))
and extraction efficiency (RE, equation (6)) were calculated by using
the slopes of the constructed curves.
SSE = Slopespiked extract/Slopestandard x 100 (4)
RA = Slopespiked sample/Slopestandard x 100 (5)
RE = Slopespiked sample/Slopespiked extract x 100 (6)
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2.3.4. Toxicokinetic analysis
A two-compartmental model was used for toxicokinetic analysis of
CIT using Phoenix® 8.1 (Pharsight, St. Louis, MO, USA). The following
toxicokinetic parameters were calculated for IV and PO administration:
maximum plasma concentration for PO (Cmax), plasma concentration at
time 0 for IV (C0), time to maximum plasma concentration (Tmax) for
PO, area under the plasma concentration−time curve from time 0 to
infinite (AUC0−inf), elimination rate constant (kel), elimination half-life
(T1/2el), total body clearance (Cl), and the volume of distribution (Vd).
The absolute oral bioavailability (F, expressed as F%) for each in-
dividual pig and chicken was calculated according to equation (7). The
Cl and Vd values after PO administration were calculated by multi-
plying the data generated by the toxicokinetic software (i.e., Vd/F and
Cl/F) by the F value from each individual animal.
=
−
−
F AUC
AUC
x% 100PO
IV
0 inf
0  inf (7)
2.3.5. Statistical analysis
All toxicokinetic parameters for each administration route were
compared between sex and species using analysis of variance (ANOVA).
Parameters were log-transformed. Plasma protein binding for each
concentration level was compared between sex using ANOVA as well. A
post hoc Tukey test was used in case the variances were equal, as
evaluated by the Levene's test. If the assumption of equal variances was
violated, a Dunnett's T3 test was performed. (SPSS 25.0 IBM, USA). The
level of significance was set at α = 0.05.
3. Results and discussion
3.1. Method validation
The extraction method was based on a generic procedure described
by De Baere et al., 2012 with few changes. For the calibration model, a
quadratic 1/x (Korzybski et al., 1967) weighed fitting was applied and
Table 5
Plasma protein binding of citrinin (CIT) at 3 different concentration levels (5, 25 and 50 ng/mL plasma) in pigs (n = 4♂ and 4♀)a and broiler chickens (n = 4♂
and 4 ♀) presented as mean ± standard deviation.
Compound Concentration (ng/mL) Protein binding (%)
Pig Broiler chicken
♂ ♀ ♂ ♀
CIT 5 91.6 ± 0.9 94.6 ± 0.6 86.0 ± 0.4 88.5 ± 1.1
HO-CIT 97.1 ± 0.9 96.3 ± 1.8 99.9 ± 0.1 99.1 ± 0.1
CIT 25 97.0 ± 0.3 97.6 ± 0.2 82.5 ± 17.2 72.1 ± 25.1
HO-CIT 97.1 ± 0.3 96.7 ± 0.3 95.3 ± 0.7 95.6 ± 1.8
CIT 50 96.0 ± 1.1 97.7 ± 0.1 69.3 ± 17.5 69.4 ± 15.9
HO-CIT 96.9 ± 0.1 96.3 ± 0.5 95.3 ± 0.4 97.2 ± 0.6
Fig. 3. Plasma concentration-time profile of dihy-
drocitrinone (HO-CIT) after a single intravenous (IV,
triangles) and oral bolus (PO, dots) of (A) 0.05 mg/kg
CIT body weight to 8 pigs (4 ♂/4 ♀) and (B)
0.25 mg/kg body weight to 8 broiler chickens (4♂/4
♀). Results are presented as mean values ±
standard deviation (SD).
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the method was successfully validated for pig and chicken plasma for
the following parameters: linearity (r, gof), LOD, LOQ, matrix effects
(SSE), apparent recovery (RA) and extraction recovery (RE) (Tables 2a
and 2b). Results for linearity were all complying with the criteria, with
r ≥ 0.99 and gof ≤ 20%. The LOQ for both mycotoxins was set at
0.1 ng/mL and verified for accuracy and precision (Table 3). Extraction
efficiency was excellent for both toxins, however, recovery results
showed a strong signal suppression for both CIT and HO-CIT (35 and
32% respectively). To compensate for these matrix effects, a13C13-CIT
labeled internal standard was added to the samples before the start of
the extraction protocol, and responses instead of area's were used for
calculation. Consequently, more adequate results for apparent recovery
were achieved (Tables 2a and 2b).
Moreover, the obtained accuracy (%) and precision (RSD, %) were
within the acceptable ranges for both pig and chicken plasma (Table 3).
The specificity test demonstrated that no interfering peaks were de-
tected in the 2.5% margin of the retention time of the analytes with S/N
values ≥ 3 (results not shown). Carryover was evaluated and for none
of the compounds signals were detected that could interfere with the
response or area of the analytes at their given retention time (results not
shown).
3.2. Animal trial
No clinical effects were observed after IV and PO administration of
CIT to the pigs and chickens. Some clinical effects could be expected
because the administration levels (0.05 mg/kg BW for pigs, 0.25 mg/kg
BW for chickens) were higher than the NOAEL (0.02 mg/kg BW) in
humans (European Food Safety Authority (EFSA), 2012). The plasma
concentration–time profiles of CIT, after a single PO or IV administra-
tion to pigs and chickens, are depicted in Fig. 2A and B respectively.
The profile for pigs shows a slight secondary peak after IV admin-
istration (0.5–2 h), possibly due to enterohepatic recirculation. This
enterohepatic recirculation was also reported by Reddy et al. (1982) in
pregnant rats after subcutaneous CIT injection (Reddy et al., 1982). The
major toxicokinetic values are presented in Table 4. Significant sex
differences (p < 0.05) were observed for AUC and Vd after IV ad-
ministration, and for Tmax and Cmax after PO administration in pigs.
Differences between sexes have been detected for other mycotoxins as
for deoxynivalenol in rodents (Pestka et al., 2017) and in humans (Vidal
et al., 2018b). Results for oral bioavailability (37 ± 12% for males,
44 ± 5% for females) reveal an incomplete absorption of the toxin in
pigs. It should be noted that this value could be even lower in the field
situation, where toxin uptake could decrease with feed intake. In this
study, animals were fasted for 12 h before oral gavage. Absolute oral
bioavailability of CIT was lower compared to that of OTA, which is 67%
for pigs (Galtier et al., 1981). In remarkable contrast, the absolute oral
bioavailability for CIT in chickens was complete, which is also the case
for OTA in broilers (Devreese et al., 2018). In addition, the distribution
volume of CIT was significantly higher (p < 0.05) for broiler chickens
compared to pigs (2.5 ± 0.8 L/kg versus 0.3 ± 0.1 L/kg respec-
tively). The higher tissue distribution and oral bioavailability could
imply a higher susceptibility to the effects of CIT for chickens compared
to pigs. Based on the few existing preliminary toxicokinetic data of CIT
in humans, our results showed volumes of distribution in pigs in the
same order of magnitude. The low Vd for CIT in pigs (0.3 L/kg) was in
accordance with the low Vd in humans (0.1 L/kg) (Degen et al., 2018).
Plasma protein binding for CIT in pigs and chickens shows a range
between 69.3 ± 17.5% and 88.5 ± 1.1% for chickens and between
91.6 ± 0.9% and 97.7 ± 0.1% for pigs (Table 5). Although biologi-
cally relevant differences were observed between pigs and chickens,
there was no statistically significant difference between species, nor
between sexes (p > 0.05). CIT seems to be strongly bound to plasma
proteins, affecting distribution volume and clearance. For HO-CIT, si-
milar results were obtained. The metabolite showed a higher protein
binding in chickens than the parent compound (Table 5). Interestingly,
similar results for protein binding were obtained for OTA in pigs
(99.9%) (Hagelberg et al., 1989) and chickens (approximately 93%)
(Devreese et al., 2018), as expected since CIT and OTA are structurally
related. It is known that OTA has a high affinity for plasma proteins
(mainly albumin). The main binding site in human serum albumin
(HSA) is the Sudlow's Site I, which is located in the cavity of subdomain
IIA (Il'ichev et al., 2002). Poór et al. (2015) demonstrated that CIT has
the same binding site, with the p-quinone form of CIT being the most
important tautomer in HSA binding. Testing the binding to HSA in the
presence of both OTA and CIT, resulted in the displacement of CIT and
the binding of OTA. This is due to the higher affinity of OTA toward
HSA compared to CIT (log K = 7.4 vs 5.3, respectively). It is reported
that the affinity of OTA towards albumin shows interspecies variability.
HSA exerts a strong protein binding (log K = 7.4), while bovine serum
albumin and rat serum albumin showed a lower affinity toward OTA
(log K = 6.48 and 6.17 respectively) (Kőszegi and Poór, 2016). In
contrast, CIT seems to have similar affinities for human, bovine, porcine
and rat serum albumin (log K = 5.3, 5.1, 5.0 and 5.5 respectively)
(Poór et al., 2015). Faisal et al. reported a similar interaction of HO-CIT
in human, bovine, porcine, and rat serum albumin (Faisal et al., 1007).
Strong protein binding correlates to a small free fraction of CIT avail-
able for renal clearance, resulting in a lower elimination rate and hence
a prolonged elimination half-life. Indeed, the elimination half-life of
CIT in pigs ranged between 17 and 26 h in this study. However, the
elimination half-life of OTA in pigs is even longer (72–120 h) (Galtier
et al., 1981; Hagelberg et al., 1989), which can again be related to the
higher affinity toward porcine serum albumin. Moreover, OTA gets
reabsorbed from the tubular lumen via organic anion transporters
(more specific the apical OAT4 transporter), prolonging its elimination
half-life (Zingerle et al., 1998). It is not known whether CIT is a
transportable substrate of OAT4, but differences at the molecular level
could explain the difference in elimination half-life.
A study on the toxicokinetics of CIT in humans (Degen et al., 2018)
reports an elimination half-life of approximately 9 h, which is lower
than the reported value in pigs in this study. However, this study on
humans was a preliminary study carried out with only 2 volunteers. In
chickens, the elimination half-life of CIT was significantly shorter, be-
tween 2 and 5 h. This result could be due to the striking statistically
significant differences in clearance of the toxin (ClIV of 9.9 ± 0.4 ml/
h/kg for pigs versus ClIV of 863.1 ± 32.8 mL/h/kg for broilers). Dif-
ferences in Cl between pigs and broilers could be explained by species
variances in glomerular filtration rate, active tubular secretion and/or
reabsorption (Riviere, 2011). Another reason why CIT persists longer in
pigs could be the saturation of biotransformation enzymes. In com-
parison, OTA has a longer elimination half-life in broilers (8–23 h)
(Devreese et al., 2018). Similar to the pig, reabsorption of OTA by the
OTA4 transporter could be the reason for slower elimination compared
to CIT. Human data concerning Cl of CIT is lacking. One preliminary
study on humans reports a Cl of 7.3 mL/min after PO administration.
However, this value was corrected for the absorbed fraction, assuming
to be the sum of CIT and HO-CIT found in urine. As CIT can be bio-
transformed in other, unknown metabolites, and other routes for
elimination are possible, the obtained value for Cl is inaccurate. Hence,
comparison to humans at this stage, is not yet possible. Likewise, the
comparison to the human Vd described above is not precise, since the
Vd was calculated using Cl.
The major phase I metabolite of CIT, HO-CIT, was detected in all
plasma samples in low, fluctuating concentrations, as depicted in Fig. 3.
The AUC0−inf for HO-CIT in pigs was 23.9 ± 10.3 ng*h/mL after IV
administration and 36.9 ± 9.9 ng*h/mL after oral administration. This
AUC value is less than 1% from the AUC of CIT after IV administration,
and 3% of the AUC of CIT after oral administration. On the other hand,
the AUC0−inf values for HO-CIT were significantly higher in broilers.
After IV administration, the AUC for HO-CIT was 171.7 ± 67.5 ng*h/
mL. In comparison to the average AUC value for CIT, this ratio is 73%.
In a similar way, the AUC for HO-CIT after oral administration of CIT
C. Meerpoel, et al. Food and Chemical Toxicology 141 (2020) 111365
7
was 165.1 ± 49.4 ng*h/mL, being 52% of the AUC value for CIT.
These results indicate that there is a major species difference in bio-
transformation of CIT, and the elimination of HO-CIT. Further research
should elucidate the biotransformation processes of CIT, using a me-
tabolomics approach. In humans, no HO-CIT was detected in the plasma
after an oral dose of 0.1 μg/kg BW. An neutral red uptake (NRU) assay
demonstrated HO-CIT to be less cytotoxic compared to CIT (Föllmann
et al., 2014). Concentrations which reduce NRU by 50% (IC50) are
3.2–4.5-fold lower for CIT than for its metabolite. Moreover, the gen-
otoxic potential of HO-CIT is much lower compared to CIT, as shown by
micronucleus assays in V79 cells. Therefore, the authors concluded that
HO-CIT is a resulting product of a detoxification reaction of CIT. In
humans, HO-CIT is considered as the major metabolite of CIT (Ali et al.,
2015). In contrast, a study in rats revealed low concentrations of this
metabolite in urine, and no metabolite was detected in the blood (Dunn
et al., 1983). This also demonstrates species differences concerning CIT
metabolism. At present, the mechanism for CIT biotransformation is not
described.
To conclude, a complete toxicokinetic profile for CIT in pigs and
chickens was described. Both similarities and differences with the
structurally related compound OTA were identified. Moreover, striking
interspecies differences for the toxicokinetics of CIT were demon-
strated. It is possible that differences in toxicokinetics also imply in-
terspecies differences in toxicity. Further research is needed to unravel
biotransformation and elimination pathways to clarify species-specific
toxicokinetic parameters. Moreover, knowledge on the kinetic para-
meters of the toxin is essential to increase understanding of its mode of
action and to evaluate animal and human health risks. Until now, the
current risk assessment for CIT for the human and animal population in
Europe is based on incomplete data (European Food Safety Authority
(EFSA), 2012). The toxicokinetic characteristics for oral and in-
travenous administration of CIT in two different major species that
resulted from this study are an important step forward in the risk
analysis of CIT, and it may contribute to a refinement of the risk as-
sessment.
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